EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Mei Zhao, Shanwen Chen, Conggui Li, Yingying Du, Ping Li

Cancers · 18.01.2023 · 15 (3) · 600

DOI: 10.3390/cancers15030600 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 18.01.2023. Verfasst von Mei Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chinese Integrative Medicine Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resectable hepatocellular carcinoma (HCC) has poor prognosis because of its high recurrence rate. Immunotherapy has been tried for neoadjuvant therapy as it has shown excellent performance in the treatment of advanced HCC. This systematic review and meta-analysis aimed to assess the reported efficacy and safety of neoadjuvant immune checkpoint inhibitors (ICIs) for resectable HCC. Electronic databases, including PubMed (MEDLINE), Embase, the Cochrane Library, and ClinicalTrials.gov were systematically searched to identify published and ongoing studies evaluating the efficacy and safety of neoadjuvant ICIs for resectable HCC up to October 2022. The odds ratio (OR) and 95% confidence interval (CI) were calculated. Heterogeneity and subgroup analyses were performed, and data quality was assessed. The study was registered with PROSPERO (registration number: CRD42022371495). A total of 193 patients from 9 studies were included in this meta-analysis. The overall pathological complete response (pCR) rate was 12.9% (95%CI, 6.7–19.1%), and major pathological response (MPR) rate was 27.3% (95%CI, 15.1–39.4%), indicating a favorable association with neoadjuvant ICIs (pCR: OR = 0.17, p < 0.00001; MPR: OR = 0.38, p = 0.001). The pooled OR values for the incidence of grade 3 to 4 treatment-related adverse events and surgical delay rate were 0.26 and 0.05, respectively, which were significantly in favor of neoadjuvant ICIs (p < 0.0001; p < 0.00001, respectively). The subgroup analyses did not demonstrate superiority of one ICI over another ICI or combination therapy. The present study found that neoadjuvant ICIs were well tolerated by patients with resectable HCC and conferred therapeutic benefits in view of histopathological response results.

Schlagwörter

Stichwörter der Autor:innen

ICIsefficacyhepatocellular carcinomaneoadjuvantsafety

Autor:innen und Institutionen

  • Department of Chinese Integrative Medicine Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China.
  • Department of Integrated Traditional Chinese and Western Medicine, Anhui Medical University, Hefei 230032, China.
  • Department of Otorhinolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China.
  • Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China.

Zitieren

APA

Zhao, M., Chen, S., Li, C., Du, Y., & Li, P. (2023). Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Cancers, 15(3), 600. https://doi.org/10.3390/cancers15030600

Vancouver

Zhao M, Chen S, Li C, Du Y, Li P. Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Cancers. 2023;15(3):600. doi:10.3390/cancers15030600

BibTeX
@article{Zhao2023,
  author = {Zhao, Mei and Chen, Shanwen and Li, Conggui and Du, Yingying and Li, Ping},
  title = {Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {3},
  pages = {600},
  doi = {10.3390/cancers15030600}
}
Kostenlos starten →